Report Overview

The Asia-Pacific fertility services market is flourishing at high rate because of the increasing prevalence of polycystic ovary syndrome (PCOS), endometriosis, thyroid diseases, uterine fibroids in people with ovaries, and hormonal balance in different genders.

Asia-Pacific Fertility Services Market- Industry Trends & Forecast Report 2027

The Asia-Pacific fertility services market was worth USD 4.6 billion in 2020 and is further projected to reach USD 12.3 billion by the year 2027, growing at the CAGR of 15.2% during the forecast period. Poor lifestyle that multiplies the rsik of infertility is one of the major factors driving the growth of the market. Moreover, the increasing prevalence of heath conditions, such as polycystic ovary syndrome (PCOS), endometriosis, thyroid diseases, uterine fibroids in people with ovaries, and hormonal balance in different genders is driving the growth of the Asia-Pacific fertility services market. As a result, demand for fertility services is increasing at a high rate in Asia-Pacific countries.

Source: BlueWeave Consulting

Asia-Pacific Fertility Services Market- Overview

Fertility services are procedures that help people prevent and treat genetics issues that can lead to infertility. The fertility service providers assist couples as well as individuals who want to attain parenthood but are unable to do so because of their medical conditions. Additionally, fertility service providers evaluate individuals to determine the cause of infertility and offer them options for parenthood from a wide array of treatment options. The two most common treatments offered by fertility clinics are intrauterine insemination (IUI), in-vitro fertilization (IVF), and fertility preservation.

Asia-Pacific Fertility Services Market Forecast and Trends

Growth Drivers

Increasing Prevalence of Infertility

The incidence of infertility is increasing every day as couples are increasingly deferring parenthood until later in life. It has been estimated that one in every four couples in developing countries are affected by infertility. According to the UNFPA (United Nations Population Fund), Eastern Asia has the lowest fertility rate in the world. Consequently, the demand for fertility services is increasing at a high rate in the region. Several factors influence fertility rates in men and women such as genetics, smoking, excessive alcohol, poor diet, etc., which propels the demand for fertility services among individuals or couples who want to attain parenthood.

Advancements in Medical Research and Technologies

The advancements in fertility treatment have opened new doors for couples as well as individuals to experience parenthood. IVF, IUI treatment, creating sperm in labs, womb transplantation, freezing of eggs and sperm, creating three-parent embryos, etc. are some of the new technologies that have helped to improve fertility treatment in the Asia Pacific region. Such treatments have made way for people who are facing infertility issues. Due to such advancements, the market is flourishing at a high rate. The Asia-Pacific fertility services market is flourishing at a high rate as a result of these advancements.

Restraints

High Cost of Fertility Services

The high cost of fertility services is one of the major restraining factors for the growth of the Asia-Pacific fertility services market. Most of these services are geared towards the urban population, which is extremely financially secure. For instance, the average cost of an IVF cycle is around USD 3,500 to USD 5,500. These costs are exclusive of any additional medicines, tests, or procedures, such as frozen embryo transfer. As a result, a large percentage of couples and individuals are unable to acquire these services, which impedes the market growth.

Impact of COVID-19 on the Asia-Pacific Fertility Services Market

The COVID-19-pandemic significantly pushed the world on the edge. Due to economic imbalance, lower wages and loss of jobs, as well as physical and mental side-effects of this sensitive period, several couples and individuals delayed their parenthood. Thus, the pandemic has had a negative impact on the Asia-Pacific fertility services market. Furthermore, several Asian countries like China, India, and South Korea were among the worst hit by COVID-19. As a result of the increasing number of COVID-19 cases, healthcare providers were already overburdened, making the delivery of treatment for anything other than COVID-19 impossible. Due to this, the demand for fertility services like IVF witnessed a sharp decline.

Asia-Pacific Fertility Services Market - By Procedure

Based on procedures, the Asia-Pacific fertility services market is segmented into IVF with ICSI, IUI, IVF without ICSI, Surrogacy, and others. Among these, the IVF without ICSI segment holds the largest market share because of the higher pregnancy success rate at 27%. However, the IVF with ICSI procedure also covers a substantial share in the market with a pregnancy success rate of 24%. The growth of this segment is also attributable to the increasing prevalence male-factor infertility cases and low sperm count.

Asia-Pacific Fertility Services Market - By Service

Based on services, the Asia-Pacific fertility services market is categorized into fresh non-donor, frozen non-donor, egg & embryo banking, fresh donor, and frozen donor. The fresh non-donor segment accounts for the largest market share as this type of service is mostly availed by couples because of the real-time availability of both eggs and sperm. In the fresh non-donor cycle, the eggs are fertilized and embryos are created in the laboratories after which the embryo transfer is performed usually either within three or five days of retrieval.

Asia-Pacific Fertility Services Market - Regional Insights

Geographically, the Asia-Pacific fertility services market is segmented into China, India, Japan, South Korea, Australia, and the rest of Asia-Pacific. Among these, India is leading the market and is emerging as a preferred destination for fertility clinics. India has around 1,500 to 2,000 fertility service centers with 400 centers enrolled and the number of such clinics is also increasing at a high rate. Adding to its leading position in the medical sector, India is likely to experience prolific growth over the next few years through its advancements in health research and affordable medical services.

Competitive Landscape

The leading market players in the Asia-Pacific fertility services market are Apollo Hospitals Dhaka, Australian Concept Infertility Medical Center, Fertility First, MEHR IVF Clinic, Genea Oxford Fertility Limited, CHA Fertility Center, Maria Fertility Hospital, Superior A.R.T, Damai Service Hospital, Bourn Hall Fertility Center, Cloudnine Fertility, Shanghai United Family Hospital, Sanno Hospital, Oak Medical Group/Oak Clinic, Bahosi Fertility Centre, and other prominent players.

The market players offer a wide range of treatment and child-bearing options for couples and individuals with various medical conditions. They also invest and engage in R&D activities to expand and improve the chances of fertility options which to gain a competitive edge. Furthermore, the fertility service providing facilities have also been embracing strategies, such as partnerships, mergers, collaborations, etc., to expand their skills and services.

Recent Developments

• In August 2021, Carrot Fertility, a global fertility benefits provider, announced to have raised USD 75 million in Series C funding led by investment firm Tiger Global Management. This funding is aimed towards product offerings for health plans and U.S. multinational employers.
• In August 2021, Unified Women’s Healthcare, a US-based healthcare practice management platform, announced the acquisition of Women’s Health USA, a practice management service provider in the women’s health sector.

Scope of the Report

By Procedure

• IVF with ICSI
• IUI
• IVF without ICSI
• Surrogacy
• Others

By Service

• Fresh Non-donor
• Frozen Non-donor
• Egg & Embryo Banking
• Fresh Donor
• Frozen Donor

By End-User

• Fertility Clinics
• Surgical Centers
• Hospitals
• Clinical Research Laboratories

By Region

• China
• India
• Japan
• South Korea
• Australia
• Rest of Asia-Pacific